Piper Jaffray Reiterates “Overweight” Rating on Genzyme Corp (NASDAQ: GENZ) - American Banking News PDF Print
American Banking NewsThe Company's product and service portfolio is focused on rare genetic disease disorders, renal diseases, orthopaedics, cancer, transplant and immune

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.